Associate Professor, Medicine-Brigham and Women's Hospital, Harvard Medical School
Oncology
Dr. Irene M. Ghobrial, MD
|
|
Give Review
Irene Ghobrial practices Oncology. She graduated from Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63 in research and 85 in primary care medicine She over the years received 1 awards: "Elected Member". Irene Ghobrial is a published doctor and has 101 publications published. The lastest was: 'Central nervous system involvement by Waldenstrm macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.'
Publications
- Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel Syndrome): a multi-institutional retrospective study.
- Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
- CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.
- American Society of Hematology Annual Meeting 2014: highlights in multiple Myeloma.
- Extramedullary Waldenström Macroglobulinemia.
- Dynamic interplay between bone and multiple Myeloma: Emerging roles of the osteoblast.
- Targeting the bone marrow microenvironment in multiple Myeloma.
- Team work matters: dual inhibition puts non-hodgkin Lymphoma under siege.
- Targeting survival and Cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
- SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy.
- How I treat smoldering multiple Myeloma.
- Pyk2 promotes tumor progression in multiple Myeloma.
- Investigating osteogenic differentiation in multiple Myeloma using a novel 3D bone marrow niche model.
- Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenstrom's Macroglobulinemia.
- Engineered nanomedicine for Myeloma and bone microenvironment targeting.
- Altered cytokine and chemokine profiles in multiple myeloma and precursor Disease.
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related Disorders: consensus from the Seventh International Workshop on WM.
- Clinical perspective: Linking psychosocial care to the Disease continuum in patients with multiple myeloma.
- Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy.
- Carfilzomib, rituximab and dexamethasone (CaRD) is active and offers a neuropathy-sparing approach for proteasome-inhibitor based therapy in Waldenstrom's macroglobuli...
- Outcomes in patients with relapsed or refractory multiple Myeloma in a phase I study of everolimus in combination with lenalidomide.
- C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic Lymphoma.
- Role of endothelial progenitor Cells in cancer progression.
- Regulation of microRNAs in Cancer metastasis.
- Waldenström Macroglobulinemia: from biology to treatment.
- A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory Myeloma.
- The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression.
- Update on Waldenström's Macroglobulinemia.
- CRM1 inhibition induces tumor Cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple Myeloma who have received lenalidomide and bortezomib.
- Molecular mechanisms of effectiveness of novel therapies in multiple Myeloma.
- Choice of therapy for patients with waldenstrom Macroglobulinemia.
- Results of the phase II trial of single agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom Macroglobulinemia.
- Endothelial stress products and Coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
- Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia.
- Would the real myeloma Cell please stand up?
- Multimodality imaging in amyloidosis.
- Serum Galactomannan and (1->3) ?-D-Glucan Assays in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia.
- P-selectin glycoprotein ligand regulates the interaction of multiple myeloma Cells with the bone marrow microenvironment.
- Multiple Myeloma-Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects.
- Defining the role of TORC1 and TORC2 in multiple Myeloma.
- Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's Macroglobulinemia.
- The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms(*).
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I...
- Management of relapsed and relapsed/refractory multiple Myeloma.
- Anti-angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia.
- BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
- Managing multiple Myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.
- The role of (18) F-FDG PET/CT imaging in Waldenstrom Macroglobulinemia.
- MGUS and smoldering myeloma: the most prevalent of plasma Cell dyscrasias.
- Targeting the bone marrow in waldenstrom Macroglobulinemia.
- The role of serum immunoglobulin free light chain in response and progression in waldenstrom Macroglobulinemia.
- FGFR3 is overexpressed Waldenstrom Macroglobulinemia and its inhibition by Dovitinib induces apoptosis, and overcomes stroma-induced proliferation.
- New insights into the pathogenesis and treatment of Waldenstrom Macroglobulinemia.
- Integrin {beta}7-mediated regulation of multiple myeloma Cell adhesion, migration, and invasion.
- A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple Myeloma.
- Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
- The bone marrow niche in Waldenström's Macroglobulinemia.
- Key role of microRNAs in Waldenström's Macroglobulinemia pathogenesis.
- Novel M-Component Based Biomarkers in Waldenström's Macroglobulinemia.
- Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple Myeloma.
- Novel agents in Waldenström Macroglobulinemia.
- Optical techniques for tracking multiple myeloma enGraftment, growth, and response to therapy.
- Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.
- microRNA-dependent modulation of histone acetylation in Waldenstrom Macroglobulinemia.
- Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple Myeloma.
- Elevated IL-17 produced by TH17 Cells promotes myeloma Cell growth and inhibits immune function in multiple myeloma.
- Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom Macroglobulinemia.
- Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom Macroglobulinemia.
- Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom Macroglobulinemia.
- Tailoring treatment for multiple myeloma patients with relapsed and refractory Disease.
- Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's Macroglobulinemia.
- Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom Macroglobulinemia.
- New Therapeutic Approaches for Waldenstrom Macroglobulinemia.
- Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple Myeloma.
- Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom Macroglobulinemia.
- Novel therapies in the treatment of multiple Myeloma.
- Primary therapy of Waldenström Macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
- RhoA and Rac1 GTPases play major and differential roles in stromal Cell-derived factor-1-induced Cell adhesion and chemotaxis in multiple myeloma.
- MicroRNAs 15a and 16 regulate tumor proliferation in multiple Myeloma.
- microRNA expression in the biology, prognosis, and therapy of Waldenström Macroglobulinemia.
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma Cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
- Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglo...
- Role of proteasome inhibition in Waldenström's Macroglobulinemia.
- High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone Lymphomas.
- Novel therapeutic agents in Waldenström's Macroglobulinemia.
- Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy.
- Endoplasmic reticulum stress is a target for therapy in Waldenstrom Macroglobulinemia.
- Increased incidence of transformation and myelodysplasia/Acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
- ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple Myeloma?
- Finding the right academic job.
- Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
- SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom Macroglobulinemia.
- Targeting NF-kappaB in Waldenstrom Macroglobulinemia.
- Dual targeting of the proteasome regulates survival and homing in Waldenstrom Macroglobulinemia.
- Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's Macroglobulinemia.
- Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma Cell cytotoxicity in the bone marrow microenvironment.
- The Akt pathway regulates survival and homing in Waldenstrom Macroglobulinemia.
- Targeting MEK induces myeloma-Cell cytotoxicity and inhibits osteoclastogenesis.
Schools
University Of Cairo Faculty Of Medicine
Cairo University Hospital
Wayne State University
Mayo Clinic
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
Education
-
Mayo School of Graduate Medical Education -
Wayne State University School of Medicine -
Cairo University School of Medicine
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1306871637 | |
| NPPES Provider LastName | GHOBRIAL | |
| NPPES Provider FirstName | IRENE | |
| NPPES Provider ZIPCode | 02215 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 284.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 5.63 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1306871637 |
| Last Name Of The Provider | GHOBRIAL |
| First Name Of The Provider | IRENE |
| View All |
Similar Doctors
|
|
Dr. Robert H. Gottlieb, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas J. Schuetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carl J. O'Hara, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Frank, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nikolaos Trikalinos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence N. Shulman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margaret A. Shipp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary-Ellen Taplin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William C. Hahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vincent T. Ho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey I. Shapiro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ian E. Krop, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven P. Treon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philippe Armand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph H. Antin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John G. Krikorian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zachary S. Spigelman, MD
This Doctor is OpenDoctor Recommended.
|